BC Innovations | Jul 20, 2017
Product R&D

Eureka moment for TCR mimics

In the race to access the wealth of intracellular molecular targets once considered undruggable, Eureka Therapeutics Inc. is pioneering TCR -like antibodies that capitalize on the ability of TCRs to recognize tumor antigens. But the...
BC Week In Review | Nov 11, 2016
Company News

Bellicum, Bambino Gesu Children's Hospital deal

Bellicum and the hospital partnered to jointly develop CAR T cell and T cell receptor (TCR) therapies discovered by the hospital and engineered with Bellicum’s CaspaCIDe molecular safety switch technology. Bellicum will provide up to...
BC Week In Review | Jun 13, 2016
Company News

Bellicum, Leiden University Medical Center deal

Bellicum and the center partnered to discover and validate high-affinity T cell receptor (TCR) candidates to treat cancer. The biotech, which will provide its CaspaCIDe switch technology, will have exclusive, worldwide rights to compounds discovered...
BC Week In Review | Jun 1, 2015
Company News

Leiden University, Bellicum deal

The university granted Bellicum exclusive, worldwide rights to high-affinity T cell receptor (TCR) products targeting solid tumors expressing the preferentially expressed antigen in melanoma (PRAME) . Bellicum plans to start Phase I/II testing of the first...
Items per page:
1 - 4 of 4